About

Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant products for all stages of the drug development pipeline from target discovery, target validation and functional genomics to predictive toxicology, personalized medicine and the search for clinical markers in blood.

Available as a service since 2001 and as catalogue products since 2003, Jivan’s flagship SpliceExpress™ arrays are the first commercial microarrays for alternative splicing. Jivan also leads with software for alternative splicing analysis and PCR primer sets for splice isoform detection.

Jivan Expands Business Focus to PCR, Software, Arrays for Alternative Splicing

(June 17, 2008) – Jivan Biologics, Inc. announced today that the company has expanded its focus to encompass multiple technologies for high-throughput alternative splicing analysis: PCR, microarrays, software and databases. In 2001 Jivan began with a focus on microarray services for alternative splicing — the industry’s first. As Jivan further developed the technology, Jivan subsequently launched the first catalog splice array, the first genome-wide splicing array, the first genome-wide PCR primer set for splice isoform detection, and the first software package designed for analyzing splicing data. Jivan believes these developments represent significant market opportunities, individually and together.

Jivan intends to broaden its focus to a complete range of products for high-throughput analysis of alternative RNA splicing, which may improve the next generation of drugs, biomarkers, diagnostics and medical research. The new focus is conveyed in Jivan’s updated tag line, “Solutions for Alternative Splicing”.

Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant microarrays, analysis software and PCR primer designs to benefit all stages of the drug development pipeline: biomarkers in blood, diagnostics, target validation, toxicology and basic research.

(May 19, 2008) – Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017. This patent is the sole subject of the suit ExonHit Therapeutics SA and ExonHit Therapeutics, Inc. filed against Jivan Biologics Inc. on March 12, 2007 in the U.S. District Court, Northern District of California.

On January 31, 2008, Jivan requested reexamination of the ‘571 patent on the basis of prior art not considered by the patent office during the original examination. The reexamination request explains the relevance of the cited prior art and the manner of applying it to each claim of the patent.

The U.S. Patent and Trademark Office (USPTO) has found that the cited prior art raises a substantial new question of patentability and has ordered reexamination of all claims of the ‘571 patent. The duration of the reexamination process is typically one year. Detailed information about the reexamination can be accessed at
http://portal.uspto.gov/external/portal/pair.

“We are pleased to hear that the USPTO has decided to reexamine the validity of this patent. We expect the patent office to consider whether claims in the ‘571 patent should be amended or invalidated in their entirety,” said Subha Srinivasan, PhD, CEO of Jivan.